A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors

ABSTRACT: This is a single-arm, open, dose-increasing phase I clinical study to explore the safety, tolerability and pharmacokinetic characteristics of the drug C-13-60 cells, and preliminarily observe the efficacy of the drug in CEA positive late malignant solid tumors, and explore the applicable dose regimen for phase II clinical trials.

DISEASE(S): Esophagus Cancer,Pancreas Cancer,Esophageal Neoplasms,Gastric Cancer,Non-small Cell Lung Cancer,Bile Duct Neoplasms,Colorectal Cancer,Bile Duct Cancer,Pancreatic Neoplasms,Breast Cancer,Cholangiocarcinoma

PROVIDER: 92434 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR